

IN THE CLAIMS:

Please amend the claims as follows:

A2 3. (Amended) A compound according to claim 1 or 2 wherein R₁ represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, methyl, or methoxy.

4. (Amended) A compound according to claim 1, wherein R₁ is methyl and R₂ is Cl.

A3 6. (Amended) A pharmaceutical composition containing as an active ingredient a compound according to claim 1 together with a pharmaceutically acceptable carrier and optionally together with a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamins D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines, β -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

7. (Amended) Use of a compound according to claim 1 for the preparation of a medicament for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory

bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne.

AB 00030970-022002
8. (Amended) A method for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne, characterised in administering to a patient suffering from at least one of said diseases an effective amount of one or more compounds according to claim 1 as an active ingredient alone, or if necessary together with a pharmaceutically acceptable carrier, and, optionally, a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines, β -adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

9. (Amended) A method of treatment according to claim 1 comprising administering to a mammal in need of systemic treatment a suitable dose of a compound of formula I of from 0.1 to 200 mg/kg

A3 bodyweight, preferably a dose of from 0.2 to 50 mg/kg of mammal
bodyweight one or more times daily.

2025-04-06 09:04:00